Esophageal cancer after endoscopic injection sclerotherapy for esophageal varices.
We reported two cases of squamous cell carcinoma of the esophagus following endoscopic injection sclerotherapy (EIS) for esophageal varices. Both patients were cigarette smokers and had a long history of alcohol abuse. HBsAg and Anti-HCV were negative, and Anti-HBs was positive in one of the patients. They were diagnosed as alcoholic cirrhosis with esophageal varices and received EIS treatment. Sotradecol was utilized as the sclerosant with a mean total volume of around 30 ml. Patients developed dysphagia at 5 and 48 months following EIS, respectively. Endoscopic examination showed stenosis and ulcerative mass at the lower portion of the esophagus. Biopsy revealed well- to moderately differentiated squamous cell carcinoma of the esophagus. We conclude that endoscopic follow-up is essential and carcinoma of the esophagus should be included in the differential diagnosis for esophageal ulceration and dysphagia following EIS, particularly in those patients with risk factors for developing esophageal carcinoma.
Ng
K W
KW
Division of Gastroenterology, Department of Internal Medicine, Far Eastern Memorial Hospital, 21, Sec. 2, Nan-Ya South Road, Panchiao, Taipei 220, Taiwan.
Tan
S W
SW
Chen
Y H
YH
Chen
H C
HC
Wu
C S
CS
Liang
C T
CT
Jiang
C F
CF
D000328:Adult; D004938:Esophageal Neoplasms / Q000209:etiology*; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015911:Sclerotherapy / Q000009:adverse effects*